Found: 63
Select item for more details and to access through your institution.
Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial.
- Published in:
- European Radiology, 2021, v. 31, n. 4, p. 1853, doi. 10.1007/s00330-020-07249-y
- By:
- Publication type:
- Article
Conjunctival Melanoma: Current Treatments and Future Options.
- Published in:
- American Journal of Clinical Dermatology, 2020, v. 21, n. 3, p. 371, doi. 10.1007/s40257-019-00500-3
- By:
- Publication type:
- Article
KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development.
- Published in:
- American Journal of Clinical Dermatology, 2019, v. 20, n. 3, p. 315, doi. 10.1007/s40257-018-0414-1
- By:
- Publication type:
- Article
Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma.
- Published in:
- EMBO Molecular Medicine, 2019, v. 11, n. 2, p. N.PAG, doi. 10.15252/emmm.201809081
- By:
- Publication type:
- Article
Novel Approaches to the Systemic Management of Uveal Melanoma.
- Published in:
- Current Oncology Reports, 2020, v. 22, n. 10, p. N.PAG, doi. 10.1007/s11912-020-00965-0
- By:
- Publication type:
- Article
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Editorial: Non-cutaneous melanoma: new therapeutic insights.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2023.1362238
- By:
- Publication type:
- Article
Keratoacanthomas associated with imatinib mesylate.
- Published in:
- 2011
- By:
- Publication type:
- Letter
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
- Published in:
- Journal of Translational Medicine, 2022, v. 20, n. 1, p. 1, doi. 10.1186/s12967-022-03592-4
- By:
- Publication type:
- Article
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 990, doi. 10.1007/s10637-022-01274-y
- By:
- Publication type:
- Article
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 5, p. 1284, doi. 10.1007/s10637-021-01088-4
- By:
- Publication type:
- Article
LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1057, doi. 10.1007/s10637-021-01084-8
- By:
- Publication type:
- Article
A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 1, p. 103, doi. 10.1007/s10637-017-0530-4
- By:
- Publication type:
- Article
Chemoreduction of Orbital Recurrence of Uveal Melanoma by Intra-Arterial Melphalan.
- Published in:
- Ocular Oncology & Pathology, 2019, v. 5, n. 3, p. 186, doi. 10.1159/000490061
- By:
- Publication type:
- Article
Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.
- Published in:
- Experimental Dermatology, 2016, v. 25, n. 7, p. 553, doi. 10.1111/exd.13030
- By:
- Publication type:
- Article
Prognostic Value of Low Tumor Burden in Patients With Melanoma.
- Published in:
- Oncology (08909091), 2018, v. 32, n. 9, p. e90
- By:
- Publication type:
- Article
Secondary Prevention Strategies for Nonmelanoma Skin Cancer.
- Published in:
- Oncology (08909091), 2018, v. 32, n. 4, p. 195
- By:
- Publication type:
- Article
Mucosal Melanoma: New Insights and Therapeutic Options for a Unique and Aggressive Disease.
- Published in:
- Oncology (08909091), 2017, v. 31, n. 11, p. e23
- By:
- Publication type:
- Article
Clinical Management of Uveal and Conjunctival Melanoma.
- Published in:
- Oncology (08909091), 2016, v. 30, n. 1, p. 29
- By:
- Publication type:
- Article
Multiregional genetic evolution of metastatic uveal melanoma.
- Published in:
- NPJ Genomic Medicine, 2021, v. 6, n. 1, p. 1, doi. 10.1038/s41525-021-00233-5
- By:
- Publication type:
- Article
A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma.
- Published in:
- Cancers, 2021, v. 13, n. 21, p. 5504, doi. 10.3390/cancers13215504
- By:
- Publication type:
- Article
Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma.
- Published in:
- Cancers, 2019, v. 11, n. 11, p. 1642, doi. 10.3390/cancers11111642
- By:
- Publication type:
- Article
Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma.
- Published in:
- Cancers, 2019, v. 11, n. 7, p. 971, doi. 10.3390/cancers11070971
- By:
- Publication type:
- Article
MicroRNA-Based Cancer Mortality Risk Scoring System and hTERT Expression in Early-Stage Oral Squamous Cell Carcinoma.
- Published in:
- Journal of Oncology, 2021, p. 1, doi. 10.1155/2021/8292453
- By:
- Publication type:
- Article
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma.
- Published in:
- Sarcoma, 2015, v. 2015, p. 1, doi. 10.1155/2015/532478
- By:
- Publication type:
- Article
DQueST: dynamic questionnaire for search of clinical trials.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.734354
- By:
- Publication type:
- Article
Treatment of uveal melanoma: where are we now?
- Published in:
- Therapeutic Advances in Medical Oncology, 2018, v. 10, n. 1, p. 1, doi. 10.1177/1758834018757175
- By:
- Publication type:
- Article
Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe.
- Published in:
- Science Translational Medicine, 2014, v. 6, n. 260, p. 1, doi. 10.1126/scitranslmed.3009524
- By:
- Publication type:
- Article
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy).
- Published in:
- 2020
- By:
- Publication type:
- journal article
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2010, v. 66, n. 6, p. 1113, doi. 10.1007/s00280-010-1269-1
- By:
- Publication type:
- Article
Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205.
- Published in:
- Science Translational Medicine, 2014, v. 6, n. 232, p. 1, doi. 10.1126/scitranslmed.3008068
- By:
- Publication type:
- Article
Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Uveal melanoma: epidemiology, etiology, and treatment of primary disease.
- Published in:
- Clinical Ophthalmology, 2017, v. 11, p. 279, doi. 10.2147/OPTH.S89591
- By:
- Publication type:
- Article
Update on the Treatment of Uveal Melanoma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2016, v. 14, n. 10, p. 768
- By:
- Publication type:
- Article
Programmed Death 1 Immune Checkpoint Inhibitors.
- Published in:
- Clinical Advances in Hematology & Oncology, 2015, v. 13, n. 12, p. 858
- By:
- Publication type:
- Article
MicroRNA‐based risk scoring system to identify early‐stage oral squamous cell carcinoma patients at high‐risk for cancer‐specific mortality.
- Published in:
- Head & Neck, 2020, v. 42, n. 8, p. 1699, doi. 10.1002/hed.26089
- By:
- Publication type:
- Article
Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response.
- Published in:
- Head & Neck, 2016, v. 38, n. 9, p. 1310, doi. 10.1002/hed.24435
- By:
- Publication type:
- Article
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients.
- Published in:
- Cancer (0008543X), 2015, v. 121, n. 1, p. 60, doi. 10.1002/cncr.28980
- By:
- Publication type:
- Article
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Clinical Activity of Ipilimumab for Metastatic Uveal Melanoma.
- Published in:
- Cancer (0008543X), 2013, v. 119, n. 20, p. 3687, doi. 10.1002/cncr.28282
- By:
- Publication type:
- Article
Augmenting advance care planning in poor prognosis cancer with a video decision aid: a preintervention-postintervention study.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Augmenting advance care planning in poor prognosis cancer with a video decision aid.
- Published in:
- Cancer (0008543X), 2012, v. 118, n. 17, p. 4331, doi. 10.1002/cncr.27423
- By:
- Publication type:
- Article
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Single-Institution Experience With Ipilimumab in Advanced Melanoma Patients in the Compassionate Use Setting.
- Published in:
- Cancer (0008543X), 2010, v. 116, n. 7, p. 1767, doi. 10.1002/cncr.24951
- By:
- Publication type:
- Article
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors.
- Published in:
- Oncologist, 2019, v. 24, n. 6, p. 857, doi. 10.1634/theoncologist.2018-0160
- By:
- Publication type:
- Article
Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.
- Published in:
- Oncologist, 2016, v. 21, n. 7, p. 848, doi. 10.1634/theoncologist.2015-0522
- By:
- Publication type:
- Article
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.
- Published in:
- Oncologist, 2015, v. 20, n. 11, p. 1245, doi. 10.1634/theoncologist.2015-0245
- By:
- Publication type:
- Article
A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
- Published in:
- Oncologist, 2015, v. 20, n. 7, p. 789, doi. 10.1634/theoncologist.2014-0012
- By:
- Publication type:
- Article